* HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL is approved. HUMIRA for Subcutaneous Injection 80 mg Syringe 0.8 mL and HUMIRA for Subcutaneous Injection 80 mg Pen 0.8 mL are yet to be ...
June 27, 2006 — The US Food and Drug Administration (FDA) has approved a pill-swallowing cup to facilitate ingestion of medications and vitamins in patients who have difficulty swallowing; an ...
HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial) of ...
Earlier this week, Sandoz announced the launch of its adalimumab biosimilar, HYRIMOZ, in 40-mg doses for subcutaneous injection in either a syringe or prefilled pen, in Spain. As we reported earlier, ...
The European Medicines Agency's Committee for Medicinal Products for Human Use recommended marketing authorization this week for two new adalimumab biosimilars, Hukyndra and Libmyris. The biosimilars, ...
Boehringer Ingelheim and GoodRx, the leading prescription savings platform in the US, announced a patient affordability initiative to provide citrate-free Adalimumab-adbm, Boehringer’s biosimilar to ...
Adalimumab (Humira, Abbott Laboratories) is a recombinant human monoclonal antibody that binds specifically to tumour necrosis factor alpha (TNF-α), blocking interaction with its cell-surface ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results